Latest News
Amgen Inc.
- Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE
- Amgen and AstraZeneca report Phase III Tezspire data for EoE
- From Discovery to Delivery: 5 Ways Amgen Is Putting Sustainability into Practice
- AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
- Amgen, AZ dive deep into Tezspire's Dupixent-challenging victory in EoE phase 3
- Is Amgen Stock Increasing Your Market Risk?
- Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com
- Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know
- Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
- Amgen Research Offers Clue to Weight-Loss Drug Paradox
- EADV 2026: Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
- BMS’s Opdivo patent suit against Amgen adds to eventful 2026 for biosimilar spats
Headlines from the last 30 days, linking to the original publishers. See all market news →